Related Experiment Videos
[Adjuvant therapy in colorectal carcinoma]
1Departement für Innere Medizin, Kantonsspital Basel.
Schweizerische Medizinische Wochenschrift
|April 25, 1992
Summary
Adjuvant chemotherapy with 5-fluorouracil and levamisole improves survival for colon cancer patients with lymph node involvement. For rectal cancer, combined chemo- and radiotherapy reduces local relapses and prolongs survival, despite potential toxicity.
Area of Science:
- Oncology
- Surgical Oncology
- Medical Oncology
Context:
- Colorectal carcinoma with lymph node involvement (N+ or Dukes' C) or advanced tumor invasion (T3-T4 or Dukes' B2-B3) carries a poor prognosis with surgery alone.
- Early postoperative chemotherapy studies in colonic cancer showed limited therapeutic benefit.
- Rectal cancer treatment has seen improvements with combined modalities, but delayed toxicities are a concern.
Purpose:
- To evaluate the efficacy of adjuvant chemotherapy and combined chemo-radiotherapy in improving outcomes for colorectal cancer patients.
- To identify effective adjuvant treatment strategies for specific stages of colon and rectal cancer.
Summary:
- The combination of 5-fluorouracil and levamisole significantly improved disease-free interval and overall survival in Dukes' C colonic cancer patients.
- For rectal cancer, combined chemo- and radiotherapy significantly reduced local relapses and prolonged overall survival.
- The 5-fluorouracil and levamisole regimen for colon cancer has minimal side effects, while combined modality for rectal cancer carries risks of delayed small bowel toxicity.
Impact:
- Establishes 5-fluorouracil and levamisole as a beneficial adjuvant therapy for specific colon cancer patients.
- Highlights the effectiveness of combined chemo-radiotherapy in rectal cancer management, necessitating careful patient selection and monitoring.
- Emphasizes the role of general practitioners and specialists in determining patient suitability for adjuvant therapies.